Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZEN 3694

Drug Profile

ZEN 3694

Alternative Names: BETi ZEN-3694; ZEN-003694; ZEN-3694

Latest Information Update: 17 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Pittsburgh; Zenith Epigenetics
  • Developer National Cancer Institute (USA); Newsoara Biopharma; Pfizer; Zenith Epigenetics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Phase I/II Carcinoma; Lymphoma
  • No development reported Haematological malignancies; Lung cancer

Most Recent Events

  • 07 Mar 2024 Zenith Epigenetics in collaboration with Pfizer and Newsoara Biopharma terminates a phase II trial in Triple-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (PO), due to the results from an interim futility analysis (NCT03901469) (EudraCT2018-003906-26)
  • 23 Jan 2024 University of Pittsburgh in collaboration with GSK initiates enrollment in a phase I clinical trial in Solid tumours (Combination therapy, Metastatic disease, Recurrent) in USA (PO) (NCT06161493)
  • 06 Dec 2023 Haider Mahdi plans a phase I trial for Solid tumours (Metastatic disease, Second-line therapy or greater, Combination therapy) in the USA (PO) in December 2023 (NCT06161493)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top